CBT-004

CBT-004 is a potential first-in-class drug candidate, which is a multi-kinase inhibitor targeting VEGFRs and PDGFRs indicated for the treatment of vascularised pinguecula. We commenced pre-clinical studies for CBT-004 in China in 2019. We obtained the IND approval from the FDA on 18 February 2021 and submitted the IND amendment on 29 September 2023 for CBT-004. We commenced phase 2 clinical trial in December 2023, and completed it in May 2025.

We developed CBT-004 through our proprietary MKI technology platform. We expect CBT-004 to be the first drug available targeting vascularised pinguecula once approved, the current standard of care for which can only temporarily alleviate symptoms.